IUPAC Name: Sodium (E,3S,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoate
Systematic of Fluvastatin sodium (CAS NO.93957-55-2): Fluvastatin ; Fluvastatin sodium [USAN] ; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, monosodium salt, (R*,S*-(E))-(+-)- ; CCRIS 6848 ; Canef ; Fluindostatin ; Fluvastatin Sanabo ; Fluvastatin sodium ; Fractal ; Lescol ; Lescol XL ; Lipaxan ; Locol ; Lymetel ; Primesin ; Sodium (+-)-(3R*,5S*,6E)-7-(3-(p-fluorophenyl)-1-isopropylindol-2-yl)-3,5-dihydroxy-6-heptenoate ; UNII-PYF7O1FV7F ; Vastin ; XU 62-320
CAS NO: 93957-55-2
Molecular Formula of Fluvastatin sodium (CAS NO.93957-55-2): C₂₄H₂₅FNNaO₄
Molecular Weight: 433.4478
Molecular Structure:

ProductCategories: Antihyperlipoproteinemic ; Intermediates & Fine Chemicals ; Pharmaceuticals ; HMG-CoA reductase
Melting Point: 194-197°C
Polar Surface Area:  60.69 ?2 
Flash Point:  366.1 °C
Enthalpy of Vaporization:  105.06 kJ/mol 
Boiling Point of Fluvastatin sodium (CAS NO.93957-55-2):  681.8 °C at 760 mmHg 
Vapour Pressure:  1.6E-19 mmHg at 25°C 

Fluvastatin Sodium is an oral antilipemic agent. Fluvastatin Sodium is given prophylactically to patients with ischaemic heart disease, including patients who have had a percutaneous coronary intervention. It is also used to reduce LDL-cholesterol, apolipoprotein B, and triglycerides, and to increase HDL-cholesterol, in the treatment of hyperlipidaemias, including hypercholesterolaemias and combined (mixed) hyperlipidaemia (type IIa or IIb hyperlipoproteinaemias).Furthermore, Fluvastatin Sodium is a HMG-CoA reductase inhibitor and is the first to be synthetically prepared.

Contraindications:
1)Hypersensitivity to drug
2)Active hepatic disease
3)Severe renal impairment
4)Pregnancy or breastfeeding